- Home
- ATEX vs SVRA Comparison
ATEX vs SVRA Comparison
Compare ATEX & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATEX
- SVRA
- Stock Information
- Founded
- ATEX 1997
- SVRA N/A
- Country
- ATEX United States
- SVRA United States
- Employees
- ATEX N/A
- SVRA N/A
- Industry
- ATEX Telecommunications Equipment
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- ATEX Telecommunications
- SVRA Health Care
- Exchange
- ATEX Nasdaq
- SVRA Nasdaq
- Market Cap
- ATEX 555.0M
- SVRA 458.2M
- IPO Year
- ATEX N/A
- SVRA N/A
- Fundamental
- Price
- ATEX $28.28
- SVRA $2.86
- Analyst Decision
- ATEX Strong Buy
- SVRA Buy
- Analyst Count
- ATEX 2
- SVRA 7
- Target Price
- ATEX $68.00
- SVRA $9.86
- AVG Volume (30 Days)
- ATEX 139.2K
- SVRA 1.0M
- Earning Date
- ATEX 02-11-2025
- SVRA 03-06-2025
- Dividend Yield
- ATEX N/A
- SVRA N/A
- EPS Growth
- ATEX N/A
- SVRA N/A
- EPS
- ATEX N/A
- SVRA N/A
- Revenue
- ATEX $5,607,000.00
- SVRA N/A
- Revenue This Year
- ATEX $53.57
- SVRA N/A
- Revenue Next Year
- ATEX $0.93
- SVRA N/A
- P/E Ratio
- ATEX N/A
- SVRA N/A
- Revenue Growth
- ATEX 97.01
- SVRA N/A
- 52 Week Low
- ATEX $27.37
- SVRA $2.59
- 52 Week High
- ATEX $42.41
- SVRA $5.70
- Technical
- Relative Strength Index (RSI)
- ATEX 42.05
- SVRA 47.32
- Support Level
- ATEX $27.72
- SVRA $2.62
- Resistance Level
- ATEX $29.99
- SVRA $2.91
- Average True Range (ATR)
- ATEX 1.40
- SVRA 0.18
- MACD
- ATEX 0.04
- SVRA 0.02
- Stochastic Oscillator
- ATEX 24.67
- SVRA 47.71
About ATEX Anterix Inc.
Anterix Inc is a United States-based company engaged in delivering broadband needed to modernize infrastructure for energy, transportation, logistics, and other industries. The company offers Private LTE for utilities which help to automate processes, monitor environmental conditions, enable artificial intelligence, and drive productivity.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.